Neonatal thyrotoxicosis treated with exchange transfusion and Lugol's iodine

1985 ◽  
Vol 143 (4) ◽  
pp. 317-319 ◽  
Author(s):  
J. M. Wit ◽  
L. J. Gerards ◽  
C. Vermeulen-Meiners ◽  
H. W. Bruinse
Keyword(s):  
Exchange Transfusion ◽  
Lugol’S Iodine ◽  
Neonatal Thyrotoxicosis

SURVIVAL TIME OF CIRCULATING LONG-ACTING THYROID STIMULATOR IN NEONATAL THYROTOXICOSIS: IMPLICATIONS FOR DIAGNOSIS AND THERAPY OF THE DISORDER

PEDIATRICS ◽  
1965 ◽  
Vol 36 (6) ◽  
pp. 869-876
Author(s):  
Philip Sunshine ◽  
Howard Kusumoto ◽  
Joseph P. Kriss
Keyword(s):  
Survival Time ◽  
Corticosteroid Therapy ◽  
Half Life ◽  
Exchange Transfusion ◽  
Maternal Serum ◽  
Periorbital Edema ◽  
Antithyroid Therapy ◽  
Long Acting ◽  
Neonatal Thyrotoxicosis ◽  
Very High

We have described an infant with neonatal thyrotoxicosis who developed supraventricular tachycandia, goiter, and periorbital edema. Both the baby's and mother's sera contained the long-acting thyroid stimulator (LATS). While the level of LATS remained unchanged in the serum of the mother, it rapidly fell in the serum of the infant. The biological half-life of LATS in the infant's serum was calculated to be 6 days, and by the age of 21 days no LATS activity could be detected. Based on these findings, antithyroidal treatment which had been instituted soon after birth was discontinued on the thirty-eighth day without recurrence of signs or symptoms of thyrotoxicosis. In addition to conventional antithyroid therapy for thyrotoxicosis, exchange transfusion and prenatal corticosteroid therapy of the mother may be considered when neonatal or maternal serum LATS titers, respectively, are very high.

CLINICAL OBSERVATION OF NEONATAL THYROTOXICOSIS

2019 ◽  
Vol 98 (2) ◽  
pp. 243-247
Author(s):  
E.E. Petryajkina ◽  
◽  
D.Y. Ovsyannikov ◽  
L.V. Pushko ◽  
I.G. Rybkina ◽  
...  
Keyword(s):  
Clinical Observation ◽  
Neonatal Thyrotoxicosis

Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion

2020 ◽  
Vol 23 ◽  
Author(s):  
Erbu Yarci ◽  
Cuneyt Tayman ◽  
Ufuk Cakir ◽  
Utku Serkant
Keyword(s):  
Exchange Transfusion ◽  
Neuronal Damage ◽  
Neuron Specific Enolase ◽  
Endothelial Damage ◽  
Control Group ◽  
Control Groups ◽  
Term Neonates ◽  
Blood Exchange ◽  
Blood Exchange Transfusion ◽  
And Control

Background:: Hyperviscosity of blood secondary to polycythemia results in increased resistance to blood flow and decrease in delivery of oxygen. Objective:: To evaluate whether serum endocan, NSE and IMA levels can be compared in terms of endothelial injury/ dysfunction and neuronal damage in term neonates with polycythemia who underwent PET. Methods:: 38 symptomatic polycythemic newborns having PET and 38 healthy newborns were included in the study. Blood samples for endocan, NSE and IMA were taken at only postnatal 24 hours of age in the control group and in polycytemia group just before PET, at 24 and 72 hours after PET. Results:: The polycythemia group had higher serum endocan(1073,4 ± 644,8 vs. 378,8 ± 95,9ng/ml; p<0.05), IMA(1,32 ± 0,34 vs.0,601 ± 0,095absorbance unit; p<0.05) and NSE(44,7 ± 4,3 vs. 26,91 ± 7,12μg/l; p<0.05) levels than control group before the PET procedure. At 24 hours after PET, IMA(0,656 ± 0,07 vs. 0,601 ± 0,095absorbance unit; p<0.05) and endocan(510,9 ± 228,6 vs. 378,8 ± 95,9ng/ml; p<0.05) levels were closer to the control group, being still statistically significant higher. NSE levels decreased to control group levels having no difference between the PET and control groups at 24 hours after PET (28,98 ± 6,5 vs. 26,91 ± 7,12μg/l; p>0.05). At 72 hours after PET the polycythemia and control groups did not differ statistically for IMA, endocan and NSE levels (p>0.05). Conclusion:: Serum endocan and IMA levels can be used as a biomarker for endothelial damage / dysfunction and tissue hypoxia in infants with symptomatic polycytemia.

Exchange transfusion in Rh haemolytic disease

Vox Sanguinis ◽  
2021 ◽  
Author(s):  
Jon F. Watchko ◽  
M. Jeffrey Maisels
Keyword(s):  
Exchange Transfusion ◽  
Haemolytic Disease
Sign in / Sign up

Export Citation Format

Share Document